The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Oxyargin 10 mg/5 mg prolonged release tablets

10 mg/ 5 milligram(s) Prolonged-release tablet

McDermott Laboratories Ltd., T/A Gerard LaboratoriesPA0577/220/002

Main Information

Trade NameOxyargin 10 mg/5 mg prolonged release tablets
Naloxone hydrochloride dihydrate
Strength10 mg/ 5 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderMcDermott Laboratories Ltd., T/A Gerard Laboratories
Licence NumberPA0577/220/002

Group Information

ATC CodeN02AA Natural opium alkaloids
N02AA55 oxycodone, combinations


Licence Issued17/11/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in Schedule 2 to the Misuse of Drugs Regulations 1988 (S.I. No. 328 of 1988), as amended.
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0102-016-024
Interchangeable List DocumentPDF of Interchangeable List
« Back